Literature DB >> 32447294

Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer.

Stephanie Alimena1,2, Lauren Scarpetti3, Erica L Blouch3, Linda Rodgers3, Kristen Shannon3, Marcela Del Carmen2, Annekathryn Goodman2, Whitfield B Growdon2, Eric Eisenhauer2, Rachel Clark Sisodia2.   

Abstract

OBJECTIVE: The National Comprehensive Cancer Network recommends that all women diagnosed with epithelial ovarian cancer undergo genetic testing, as the diagnosis of pathogenic variants may inform cancer survival and impact treatment options. The objective of this study was to assess factors associated with referral to genetic counseling in women with epithelial ovarian cancer.
METHODS: A retrospective cohort study identified women with epithelial ovarian cancer from 2012 to 2017 at Massachusetts General Hospital and North Shore Medical Center, a community hospital affiliated with Massachusetts General Hospital. Multivariate logistic regression evaluated how race, age, stage, year of diagnosis, insurance status, family history of breast or ovarian cancer, and language relates to the receipt of genetic counseling.
RESULTS: Of the total 276 women included, 73.9% were referred for genetic screening, of which 90.7% attended a genetic counseling visit. Older women were less likely to undergo genetic counseling (age ≥70 years: OR 0.26, 95% CI 0.07-0.94, p=0.04). Women who died within 365 days of initial oncology consult rarely reached a genetic counselor (OR 0.05, 95% CI 0.01-0.24, p<0.001). Women with a family history of breast or ovarian cancer were more likely to undergo counseling (OR 3.27, 95% CI 1.74-6.15, p<0.001). There was no difference in receipt of genetic counseling by race, stage, year of diagnosis, insurance status, or language.
CONCLUSION: Older women with epithelial ovarian cancer and those who died within 1 year of initiation of care were less likely to undergo recommended genetic counseling. Race, insurance status, and language were not identified as predictive factors, although we were limited in this assessment by small sample size. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gynecology; neoplasms; ovarian cancer

Year:  2020        PMID: 32447294     DOI: 10.1136/ijgc-2019-001168

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  1 in total

1.  Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.

Authors:  Jenny Lin; Ravi N Sharaf; Rachel Saganty; Danyal Ahsan; Julia Feit; Andrea Khoury; Hannah Bergeron; Eloise Chapman-Davis; Evelyn Cantillo; Kevin Holcomb; Stephanie V Blank; Ying Liu; Charlene Thomas; Paul J Christos; Drew N Wright; Steven Lipkin; Kenneth Offit; Melissa K Frey
Journal:  Gynecol Oncol       Date:  2021-05-19       Impact factor: 5.304

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.